End-of-day quote
NSE India S.E.
06:00:00 2024-07-07 pm EDT
|
5-day change
|
1st Jan Change
|
836.2
INR
|
-3.14%
|
|
-2.26%
|
+57.90%
|
Fiscal Period: März |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,159
|
1,678
|
540.4
|
1,487
|
2,114
|
1,542
|
Enterprise Value (EV)
1 |
1,428
|
2,127
|
1,165
|
2,028
|
2,878
|
2,511
|
P/E ratio
|
17.8
x
|
9.4
x
|
5.31
x
|
11
x
|
8.35
x
|
13.5
x
|
Yield
|
-
|
0.27%
|
-
|
0.3%
|
0.21%
|
0.29%
|
Capitalization / Revenue
|
0.54
x
|
0.44
x
|
0.21
x
|
0.56
x
|
0.6
x
|
0.49
x
|
EV / Revenue
|
0.67
x
|
0.56
x
|
0.45
x
|
0.76
x
|
0.82
x
|
0.8
x
|
EV / EBITDA
|
10.8
x
|
6.11
x
|
4.67
x
|
6.82
x
|
8.5
x
|
8.91
x
|
EV / FCF
|
32.6
x
|
-173
x
|
-6.75
x
|
127
x
|
-5.04
x
|
-6
x
|
FCF Yield
|
3.07%
|
-0.58%
|
-14.8%
|
0.78%
|
-19.9%
|
-16.7%
|
Price to Book
|
1.31
x
|
1.58
x
|
0.47
x
|
1.15
x
|
1.39
x
|
0.91
x
|
Nbr of stocks (in thousands)
|
3,023
|
3,023
|
3,023
|
3,023
|
3,023
|
3,023
|
Reference price
2 |
383.2
|
555.0
|
178.8
|
491.8
|
699.2
|
510.0
|
Announcement Date
|
9/24/18
|
9/6/19
|
9/8/20
|
9/8/21
|
9/8/22
|
9/7/23
|
Fiscal Period: März |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
2,130
|
3,779
|
2,608
|
2,656
|
3,497
|
3,156
|
EBITDA
1 |
132.6
|
348.4
|
249.3
|
297.4
|
338.5
|
282
|
EBIT
1 |
75.61
|
284.7
|
175.8
|
223.9
|
243.3
|
180.5
|
Operating Margin
|
3.55%
|
7.53%
|
6.74%
|
8.43%
|
6.96%
|
5.72%
|
Earnings before Tax (EBT)
1 |
63.97
|
253.8
|
146.7
|
195.7
|
327.3
|
165.9
|
Net income
1 |
65.01
|
178.5
|
101.8
|
135.6
|
253.2
|
114.6
|
Net margin
|
3.05%
|
4.72%
|
3.9%
|
5.1%
|
7.24%
|
3.63%
|
EPS
2 |
21.50
|
59.03
|
33.68
|
44.84
|
83.76
|
37.92
|
Free Cash Flow
1 |
43.85
|
-12.27
|
-172.4
|
15.91
|
-571.5
|
-418.7
|
FCF margin
|
2.06%
|
-0.32%
|
-6.61%
|
0.6%
|
-16.34%
|
-13.27%
|
FCF Conversion (EBITDA)
|
33.06%
|
-
|
-
|
5.35%
|
-
|
-
|
FCF Conversion (Net income)
|
67.45%
|
-
|
-
|
11.74%
|
-
|
-
|
Dividend per Share
|
-
|
1.500
|
-
|
1.500
|
1.500
|
1.500
|
Announcement Date
|
9/24/18
|
9/6/19
|
9/8/20
|
9/8/21
|
9/8/22
|
9/7/23
|
Fiscal Period: Marzo |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
269
|
449
|
624
|
541
|
764
|
969
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
2.03
x
|
1.289
x
|
2.504
x
|
1.818
x
|
2.257
x
|
3.436
x
|
Free Cash Flow
1 |
43.8
|
-12.3
|
-172
|
15.9
|
-571
|
-419
|
ROE (net income / shareholders' equity)
|
7.64%
|
18.3%
|
9.17%
|
11.1%
|
17.2%
|
6.44%
|
ROA (Net income/ Total Assets)
|
2.69%
|
7.97%
|
4.2%
|
5.04%
|
4.61%
|
3%
|
Assets
1 |
2,421
|
2,240
|
2,422
|
2,690
|
5,488
|
3,819
|
Book Value Per Share
2 |
292.0
|
352.0
|
383.0
|
427.0
|
504.0
|
558.0
|
Cash Flow per Share
2 |
1.440
|
7.190
|
7.100
|
28.20
|
3.260
|
4.230
|
Capex
1 |
35
|
244
|
234
|
356
|
512
|
486
|
Capex / Sales
|
1.64%
|
6.46%
|
8.96%
|
13.39%
|
14.63%
|
15.39%
|
Announcement Date
|
9/24/18
|
9/6/19
|
9/8/20
|
9/8/21
|
9/8/22
|
9/7/23
|
|
1st Jan change
|
Capi.
|
---|
| +57.90% | 31.26M | | +57.48% | 823B | | -7.18% | 353B | | +15.37% | 320B | | +7.45% | 295B | | +13.62% | 239B | | +14.55% | 220B | | -0.33% | 219B | | +8.14% | 167B | | -2.99% | 159B |
Other Pharmaceuticals
|